At the forthcoming Annual Stockholders’ Meeting on April 26, 2024, Bayer AG will present several candidates for election to its Supervisory Board. The Board, in its recent session, has endorsed three independent nominees: Dr. Nancy Simonian (63), a distinguished figure in biotechnology; Lori Schechter (62), renowned for her expertise in litigation; and Jeffrey Ubben (62), the founder of Inclusive Capital Partners. Additionally, Ertharin Cousin (66) and Horst Baier (67) are nominated for re-election. Notably, Dr. Simone Bagel-Trah (55) and Prof. Dr. Otmar Wiestler (67) will not seek re-election. Furthermore, Dr. Norbert W. Bischofberger (68) is resigning due to other commitments.
Prof. Dr. Norbert Winkeljohann, Chairman of the Supervisory Board, expressed enthusiasm about the candidates, highlighting their diverse and extensive backgrounds, which will augment the Board’s capabilities in crucial areas such as scientific research, litigation, and capital markets. Dr. Nancy Simonian, with her extensive experience in biotechnology and product development, is poised to contribute significantly. Lori Schechter brings her legal acumen, honed during her tenure as General Counsel of a major US healthcare company. Jeffrey Ubben’s renowned expertise in investment and capital markets will complement the Board’s profile.
Dr. Simonian, who served as CEO of Syros Pharmaceuticals until 2023, holds an impressive track record in both academia and industry. Similarly, Schechter’s career, including her tenure at McKesson Corporation, underscores her legal prowess. Ubben’s distinguished career in investment management and his commitment to sustainable practices further enhance the Board’s breadth of expertise.
The addition of these esteemed individuals reflects Bayer’s commitment to strengthening its governance and strategic direction. If elected, Ubben will step down from Bayer’s Sustainability Council, where he has been a member since February 2023.
